Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiomaximaFRA:944 +4.53%51 Median PS Value is €2.39 as of Jul. 21, 2026, which is 100% below its 10-year median of 1.36. GuruFocus rates FRA:944 with a GF Score™ of 51/100 and a GF Value™ of €2.99. The stock has 4 warning signs investors should review. Among 88 Medical Diagnostics & Research companies, Biomaxima ranks better than 55.68% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Biomaxima's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €3.235. Biomaxima's 10-Year median PS Ratio is 0.7388. Therefore, the Median PS Value for today is €2.39.
As of today (2026-07-21), Biomaxima's share price is €1.894. Biomaxima's Median PS Value is €2.39. Therefore, Biomaxima's Price to Median PS Value for today is 0.79.
The historical rank and industry rank for Biomaxima's Median PS Value or its related term are showing as below:
FRA:944'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.76 Med: 1.36 Max: 3.16
Current: 0.79
During the past 13 years, the highest Price to Median PS Value of Biomaxima was 3.16. The lowest was 0.76. And the median was 1.36.
FRA:944's Price-to-Median-PS-Value is ranked better than 55.68% of 88
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.89
vs FRA:944: 0.79
Biomaxima (FRA:944) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Biomaxima's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1.894
/
2.39
=
0.79
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomaxima Median PS Value Related Terms
Biomaxima Median PS Value Historical Data
* Premium members only.
The historical data trend for Biomaxima's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:944 vs TMO, DHR, IDXX: Median PS Value Comparison
For the Diagnostics & Research subindustry, Biomaxima's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomaxima Price-to-Median-PS-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biomaxima's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Biomaxima's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.7388.
Biomaxima's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.235.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomaxima (FRA:944) has a Median PS Value of €2.39 as of Jul. 21, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Biomaxima and its competitors. This is 76% above median its historical median of 1.36. Over the past decade, Biomaxima's Median PS Value has ranged from 0.76 to 3.16. According to the industry distribution chart, Biomaxima ranks #39 out of 88 companies in the Medical Diagnostics & Research industry, placing it in the top 44.3%.
Is Biomaxima's Median PS Value too high?
Biomaxima's current Median PS Value of €2.39 is 76% above median its 10-year median of 1.36. Over the past 10 years, this metric has ranged from a low of 0.76 to a high of 3.16. Based on the distribution chart, Biomaxima ranks #39 out of 88 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Biomaxima has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Biomaxima's Median PS Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biomaxima ranks #39 out of 88 companies for Median PS Value. This puts Biomaxima in the upper half of its industry. The industry median Median PS Value is 0.89. Historically, Biomaxima's own Median PS Value has ranged from 0.76 to 3.16 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Diagnostics & Research company?
The median Median PS Value among Medical Diagnostics & Research companies is 0.89, based on 88 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Biomaxima and its competitors. For the Medical Diagnostics & Research industry, the median Median PS Value is 0.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomaxima's current Median PS Value is €2.39, which is 76% above median its own 10-year median of 1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomaxima stock overvalued right now?
Biomaxima (FRA:944) has a current Median PS Value of €2.39. The stock's GF Value™ is €2.99, compared to a current price of €1.89 — trading 36.7% below its estimated fair value. The current Median PS Value is €2.39, which is 76% above median its 10-year median of 1.36. Biomaxima's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Biomaxima (FRA:944), the current Median PS Value is €2.39 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biomaxima (FRA:944) Overvalued in 2026?
Based on GuruFocus' analysis, Biomaxima stock appears to be undervalued.
The current stock price of €1.89 is trading 36.7% below its estimated GF Value™ of €2.99.
Key valuation signals for FRA:944:
Median PS Value: €2.39 (76% above median its 10-year median of 1.36)
GF Value™: €2.99 vs. price of €1.89 (36.7% below fair value)
No single metric tells the full story. See the FRA:944 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMaxima SA is a Polish company operating in the market of laboratory diagnostics. It is a manufacturer of microbiological substrates as well as a wide range of reagents and diagnostic equipment. The company is also a distributor of products of recognized multinational diagnostic companies such as: Accelerate Diagnostics, Nova Biomedical, PHC Group, Technoclone, Kabe and Biolog.
51GF Score
Get the complete analysis for FRA:944
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:944 has been successfully added to your 
